TrialJCI insight2019

Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.

Suresh Gopi Kalathil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.